❌

Reading view

Why Chain of Thought Fails in Clinical Text Understanding

arXiv:2509.21933v2 Announce Type: replace-cross Abstract: Large language models (LLMs) are increasingly being applied to clinical care, a domain where both accuracy and transparent reasoning are critical for safe and trustworthy deployment. Chain-of-thought (CoT) prompting, which elicits step-by-step reasoning, has demonstrated improvements in performance and interpretability across a wide range of tasks. However, its effectiveness in clinical contexts remains largely unexplored, particularly in the context of electronic health records (EHRs), the primary source of clinical documentation, which are often lengthy, fragmented, and noisy. In this work, we present the first large-scale systematic study of CoT for clinical text understanding. We assess 95 advanced LLMs on 87 real-world clinical text tasks, covering 9 languages and 8 task types. Contrary to prior findings in other domains, we observe that 86.3\% of models suffer consistent performance degradation in the CoT setting. More capable models remain relatively robust, while weaker ones suffer substantial declines. To better characterize these effects, we perform fine-grained analyses of reasoning length, medical concept alignment, and error profiles, leveraging both LLM-as-a-judge evaluation and clinical expert evaluation. Our results uncover systematic patterns in when and why CoT fails in clinical contexts, which highlight a critical paradox: CoT enhances interpretability but may undermine reliability in clinical text tasks. This work provides an empirical basis for clinical reasoning strategies of LLMs, highlighting the need for transparent and trustworthy approaches.
  •  

Life-Code: Central Dogma Modeling with Multi-Omics Sequence Unification

arXiv:2502.07299v3 Announce Type: replace-cross Abstract: The interactions between DNA, RNA, and proteins are fundamental to biological processes, as illustrated by the central dogma of molecular biology. Although modern biological pre-trained models have achieved great success in analyzing these macromolecules individually, their interconnected nature remains underexplored. This paper follows the guidance of the central dogma to redesign both the data and model pipeline and offers a comprehensive framework, Life-Code, that spans different biological functions. As for data flow, we propose a unified pipeline to integrate multi-omics data by reverse-transcribing RNA and reverse-translating amino acids into nucleotide-based sequences. As for the model, we design a codon tokenizer and a hybrid long-sequence architecture to encode the interactions between coding and non-coding regions through masked modeling pre-training. To model the translation and folding process with coding sequences, Life-Code learns protein structures of the corresponding amino acids by knowledge distillation from off-the-shelf protein language models. Such designs enable Life-Code to capture complex interactions within genetic sequences, providing a more comprehensive understanding of multi-omics with the central dogma. Extensive experiments show that Life-Code achieves state-of-the-art results on various tasks across three omics, highlighting its potential for advancing multi-omics analysis and interpretation.
  •  

BLM$_1$: A Boundless Large Model for Cross-Space, Cross-Task, and Cross-Embodiment Learning

arXiv:2510.24161v1 Announce Type: new Abstract: Multimodal large language models (MLLMs) have advanced vision-language reasoning and are increasingly deployed in embodied agents. However, significant limitations remain: MLLMs generalize poorly across digital-physical spaces and embodiments; vision-language-action models (VLAs) produce low-level actions yet lack robust high-level embodied reasoning; and most embodied large language models (ELLMs) are constrained to digital-space with poor generalization to the physical world. Thus, unified models that operate seamlessly across digital and physical spaces while generalizing across embodiments and tasks remain absent. We introduce the \textbf{Boundless Large Model (BLM$_1$)}, a multimodal spatial foundation model that preserves instruction following and reasoning, incorporates embodied knowledge, and supports robust cross-embodiment control. BLM$_1$ integrates three key capabilities -- \textit{cross-space transfer, cross-task learning, and cross-embodiment generalization} -- via a two-stage training paradigm. Stage I injects embodied knowledge into the MLLM through curated digital corpora while maintaining language competence. Stage II trains a policy module through an intent-bridging interface that extracts high-level semantics from the MLLM to guide control, without fine-tuning the MLLM backbone. This process is supported by a self-collected cross-embodiment demonstration suite spanning four robot embodiments and six progressively challenging tasks. Evaluations across digital and physical benchmarks show that a single BLM$_1$ instance outperforms four model families -- MLLMs, ELLMs, VLAs, and GMLMs -- achieving $\sim\!\textbf{6%}$ gains in digital tasks and $\sim\!\textbf{3%}$ in physical tasks.
  •  

Generative AI in Depth: A Survey of Recent Advances, Model Variants, and Real-World Applications

arXiv:2510.21887v1 Announce Type: cross Abstract: In recent years, deep learning based generative models, particularly Generative Adversarial Networks (GANs), Variational Autoencoders (VAEs), and Diffusion Models (DMs), have been instrumental in in generating diverse, high-quality content across various domains, such as image and video synthesis. This capability has led to widespread adoption of these models and has captured strong public interest. As they continue to advance at a rapid pace, the growing volume of research, expanding application areas, and unresolved technical challenges make it increasingly difficult to stay current. To address this need, this survey introduces a comprehensive taxonomy that organizes the literature and provides a cohesive framework for understanding the development of GANs, VAEs, and DMs, including their many variants and combined approaches. We highlight key innovations that have improved the quality, diversity, and controllability of generated outputs, reflecting the expanding potential of generative artificial intelligence. In addition to summarizing technical progress, we examine rising ethical concerns, including the risks of misuse and the broader societal impact of synthetic media. Finally, we outline persistent challenges and propose future research directions, offering a structured and forward looking perspective for researchers in this fast evolving field.
  •  

Metastatic brain tumors: from development to cutting-edge treatment

MedComm (2020). 2024 Dec 20;6(1):e70020. doi: 10.1002/mco2.70020. eCollection 2025 Jan.

ABSTRACT

Metastatic brain tumors, also called brain metastasis (BM), represent a challenging complication of advanced tumors. Tumors that commonly metastasize to the brain include lung cancer and breast cancer. In recent years, the prognosis for BM patients has improved, and significant advancements have been made in both clinical and preclinical research. This review focuses on BM originating from lung cancer and breast cancer. We briefly overview the history and epidemiology of BM, as well as the current diagnostic and treatment paradigms. Additionally, we summarize multiomics evidence on the mechanisms of tumor occurrence and development in the era of artificial intelligence and discuss the role of the tumor microenvironment. Preclinically, we introduce the establishment of BM models, detailed molecular mechanisms, and cutting-edge treatment methods. BM is primarily treated with a comprehensive approach, including local treatments such as surgery and radiotherapy. For lung cancer, targeted therapy and immunotherapy have shown efficacy, while in breast cancer, monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates are effective in BM. Multiomics approaches assist in clinical diagnosis and treatment, revealing the complex mechanisms of BM. Moreover, preclinical agents often need to cross the blood-brain barrier to achieve high intracranial concentrations, including small-molecule inhibitors, nanoparticles, and peptide drugs. Addressing BM is imperative.

PMID:39712454 | PMC:PMC11661909 | DOI:10.1002/mco2.70020

  •  

Metastatic brain tumors: from development to cutting-edge treatment

MedComm (2020). 2024 Dec 20;6(1):e70020. doi: 10.1002/mco2.70020. eCollection 2025 Jan.

ABSTRACT

Metastatic brain tumors, also called brain metastasis (BM), represent a challenging complication of advanced tumors. Tumors that commonly metastasize to the brain include lung cancer and breast cancer. In recent years, the prognosis for BM patients has improved, and significant advancements have been made in both clinical and preclinical research. This review focuses on BM originating from lung cancer and breast cancer. We briefly overview the history and epidemiology of BM, as well as the current diagnostic and treatment paradigms. Additionally, we summarize multiomics evidence on the mechanisms of tumor occurrence and development in the era of artificial intelligence and discuss the role of the tumor microenvironment. Preclinically, we introduce the establishment of BM models, detailed molecular mechanisms, and cutting-edge treatment methods. BM is primarily treated with a comprehensive approach, including local treatments such as surgery and radiotherapy. For lung cancer, targeted therapy and immunotherapy have shown efficacy, while in breast cancer, monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates are effective in BM. Multiomics approaches assist in clinical diagnosis and treatment, revealing the complex mechanisms of BM. Moreover, preclinical agents often need to cross the blood-brain barrier to achieve high intracranial concentrations, including small-molecule inhibitors, nanoparticles, and peptide drugs. Addressing BM is imperative.

PMID:39712454 | PMC:PMC11661909 | DOI:10.1002/mco2.70020

  •  
❌